Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma: Journal of Clinical Oncology: Vol 0, No 0 - 0 views
-
Nathan Goodyear on 13 Sep 18monoclonal Ab used in sequence with AVD found to have event-free survival, progression-free survival, and overal survival rates of 80%, 84%, and 93% respectively in older adults with Hodgkin's lymphoma.